Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$55.75 +0.2%	$44.39	$21.02 ▼ $58.40	$4.44B	-0.16	1.01 million shs	1.52 million shs
KROS Keros Therapeutics	$13.66 +0.7%	$13.89	$9.12 ▼ $72.37	$554.80M	1.31	864,466 shs	587,268 shs
RXRX Recursion Pharmaceuticals	$5.00 +1.6%	$4.91	$3.79 ▼ $12.36	$2.03B	0.84	15.09 million shs	26.97 million shs
SLN Silence Therapeutics	$5.06 -5.1%	$4.18	$1.97 ▼ $22.47	$151.45M	1.41	303,898 shs	36,805 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	0.00%	+2.47%	+43.09%	+24.10%	+131.94%
KROS Keros Therapeutics	0.00%	-9.84%	-3.62%	+16.70%	-72.53%
RXRX Recursion Pharmaceuticals	0.00%	-10.38%	+7.89%	-28.07%	-46.87%
SLN Silence Therapeutics	0.00%	-2.02%	+21.97%	+36.67%	-72.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKRO Akero Therapeutics	3.6283 of 5 stars	3.5	1.0	4.7	1.9	1.7	0.0
KROS Keros Therapeutics	3.6391 of 5 stars	4.3	3.0	0.0	1.9	5.0	0.0
RXRX Recursion Pharmaceuticals	1.9379 of 5 stars	3.2	1.0	0.0	3.0	1.7	0.6
SLN Silence Therapeutics	2.6594 of 5 stars	3.4	4.0	0.0	1.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKRO Akero Therapeutics	3.00	Buy	$82.50	47.98% Upside
KROS Keros Therapeutics	2.50	Moderate Buy	$30.56	123.69% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	40.00% Upside
SLN Silence Therapeutics	2.71	Moderate Buy	$33.83	568.64% Upside

Current Analyst Ratings Breakdown

Latest SLN, KROS, AKRO, and RXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
6/13/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
6/13/2025	SLN Silence Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
6/10/2025	KROS Keros Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$32.00 ➝ $18.00
5/30/2025	KROS Keros Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$15.00
5/27/2025	AKRO Akero Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$63.00 ➝ $64.00
5/13/2025	AKRO Akero Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $78.00
5/12/2025	KROS Keros Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$41.00 ➝ $26.00
5/9/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$4.00 ➝ $3.00
5/9/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $25.00
5/9/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $35.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$9.61 per share	N/A
KROS Keros Therapeutics	$214.71M	2.58	N/A	N/A	$11.09 per share	1.23
RXRX Recursion Pharmaceuticals	$59.82M	33.98	N/A	N/A	$1.98 per share	2.53
SLN Silence Therapeutics	$27.70M	5.47	N/A	N/A	$0.71 per share	7.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKRO Akero Therapeutics	-$151.76M	-$1.95	N/A	N/A	N/A	N/A	-32.46%	-29.83%	8/8/2025 (Estimated)
KROS Keros Therapeutics	-$152.99M	-$0.18	N/A	N/A	N/A	-27,890.94%	-41.74%	-38.42%	8/6/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$328.07M	-$1.77	N/A	N/A	N/A	-579.52%	-76.56%	-55.68%	8/6/2025 (Estimated)
SLN Silence Therapeutics	-$53.82M	-$1.50	N/A	N/A	N/A	-342.00%	-62.81%	-33.89%	8/21/2025 (Estimated)

Latest SLN, KROS, AKRO, and RXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A
5/8/2025	Q1 2025	SLN Silence Therapeutics	-$0.18	-$0.60	-$0.42	-$0.60	$3.58 million	$0.14 million
5/6/2025	Q1 2025	KROS Keros Therapeutics	-$0.01	$3.62	+$3.63	$3.62	$84.62 million	$211.25 million
5/5/2025	Q1 2025	RXRX Recursion Pharmaceuticals	-$0.44	-$0.50	-$0.06	-$0.50	$18.12 million	$14.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKRO Akero Therapeutics	0.05	17.25	17.25
KROS Keros Therapeutics	N/A	19.03	19.03
RXRX Recursion Pharmaceuticals	0.04	4.35	4.35
SLN Silence Therapeutics	N/A	9.31	9.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKRO Akero Therapeutics	N/A
KROS Keros Therapeutics	71.56%
RXRX Recursion Pharmaceuticals	89.06%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
AKRO Akero Therapeutics	7.07%
KROS Keros Therapeutics	20.60%
RXRX Recursion Pharmaceuticals	8.43%
SLN Silence Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKRO Akero Therapeutics	30	79.72 million	64.26 million	Optionable
KROS Keros Therapeutics	100	40.62 million	31.23 million	Optionable
RXRX Recursion Pharmaceuticals	400	406.50 million	329.18 million	Optionable
SLN Silence Therapeutics	100	29.93 million	N/A	Not Optionable

SLN, KROS, AKRO, and RXRX Headlines

Recent News About These Companies

Wall Street Zen Upgrades Silence Therapeutics (NASDAQ:SLN) to "Hold"

June 16 at 1:31 AM | americanbankingnews.com

Silence Therapeutics' (SLN) "Buy" Rating Reiterated at Chardan Capital

June 16 at 1:31 AM | americanbankingnews.com

Silence Therapeutics' (SLN) "Buy" Rating Reaffirmed at HC Wainwright

June 15 at 1:45 AM | americanbankingnews.com

Silence Therapeutics (NASDAQ:SLN) Rating Increased to Hold at Wall Street Zen

June 14 at 2:16 AM | marketbeat.com

HC Wainwright Reiterates "Buy" Rating for Silence Therapeutics (NASDAQ:SLN)

June 13 at 8:16 AM | marketbeat.com

Silence Therapeutics (NASDAQ:SLN) Receives Buy Rating from Chardan Capital

June 13 at 8:16 AM | marketbeat.com

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

June 12, 2025 | businesswire.com

Brokerages Set Silence Therapeutics plc (NASDAQ:SLN) PT at $33.83

June 10, 2025 | americanbankingnews.com

Silence Therapeutics plc (NASDAQ:SLN) Receives Average Rating of "Moderate Buy" from Analysts

June 7, 2025 | marketbeat.com

Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet

June 6, 2025 | zacks.com

Silence Therapeutics plc (NASDAQ:SLN) Short Interest Update

June 4, 2025 | marketbeat.com

Millennium Management LLC Reduces Stock Position in Silence Therapeutics plc (NASDAQ:SLN)

June 1, 2025 | marketbeat.com

Silence Therapeutics plc (NASDAQ:SLN) Shares Acquired by Bank of America Corp DE

June 1, 2025 | marketbeat.com

Silence Therapeutics plc (NASDAQ:SLN) Shares Bought by Woodline Partners LP

May 27, 2025 | marketbeat.com

Point72 Asset Management L.P. Has $4.36 Million Stock Position in Silence Therapeutics plc (NASDAQ:SLN)

May 22, 2025 | marketbeat.com

Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade

May 21, 2025 | zacks.com

Silence Therapeutics plc GAAP EPS of -C$0.20

May 8, 2025 | seekingalpha.com

Silence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | finanznachrichten.de

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | businesswire.com

Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying

April 23, 2025 | insidermonkey.com

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

March 5, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN, KROS, AKRO, and RXRX Company Descriptions

Akero Therapeutics NASDAQ:AKRO

$55.75 +0.13 (+0.23%)

Closing price 04:00 PM Eastern

Extended Trading

$55.28 -0.47 (-0.83%)

As of 06:08 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Keros Therapeutics NASDAQ:KROS

$13.66 +0.10 (+0.74%)

Closing price 04:00 PM Eastern

Extended Trading

$13.59 -0.07 (-0.48%)

As of 07:09 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Recursion Pharmaceuticals NASDAQ:RXRX

$5.00 +0.08 (+1.63%)

Closing price 04:00 PM Eastern

Extended Trading

$4.93 -0.07 (-1.40%)

As of 08:00 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Silence Therapeutics NASDAQ:SLN

$5.06 -0.27 (-5.07%)

Closing price 04:00 PM Eastern

Extended Trading

$5.18 +0.12 (+2.37%)

As of 06:39 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time